What Wall Street is watching
Investors want to know if Eli Lilly is experiencing the same pricing pressures on its blockbuster weight-loss drug Zepbound that…
Eli Lilly and company
FDA says Eli Lilly's Zepbound and Mounjaro are available after shortage
An injection pen for Eli Lilly's weight-loss drug Zepbound is displayed in New York City, Dec. 11, 2023. Brendan McDermid…
Eli Lilly's Zepbound weight-loss drug cuts heart failure risks, study finds
An Eli Lilly & Co. Zepbound injection pen is prepared in the Brooklyn borough of New York, U.S., on Thursday,…
GLP-1s are being tested for uses beyond weight loss and diabetes
Slimming syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Image…
GEHC gives reasons to look beyond China's temporary woes and stocks rise again
GE Healthcare reported a mixed second quarter on Wednesday morning, and shares initially dipped sharply. Shares then reversed higher as…
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
These are the top pharmaceutical stocks selected by JPMorgan for its results
JPMorgan is eyeing some drugmakers ahead of their earnings reports as investors continue to sell shares of major technology companies.…
These drugmakers are catching up to Eli Lilly and Novo Nordisk
The lucrative market for weight-loss drugs won’t be a duopoly forever. With billions at stake, that’s been a virtual guarantee…
Biogen Eisai's Leqembi Alzheimer's drug rejected by EU regulator
European drug regulators on Friday rejected Leqembi's Alzheimer's treatment Biogen and Eisaicreating another hurdle for companies as they struggle to…
Fund manager of names in weight loss and biotechnology
Weight-loss drugs have sparked investor interest and shaken up other sectors over the past year. Novo Nordisk and Eli Lilly…